REGULAR CONTENT
Final ID
598
Type
Educational Exhibit-Poster Only
Authors
S Behravesh1, Y Zhang2, P Hoang3, S Naidu1, E Huettl3, M Knuttinen1, A Deipolyi4, R Oklu3
Institutions
1Mayo Clinic Arizona, Scottsdale, AZ, 2Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 3Mayo Clinic Arizona, Phoenix, AZ, 4Memorial-Sloan Kettering Cancer Center, New York, NY
Purpose
To review current and future applications of microfluidic bioreactors. To highlight the potential of lab-on-a-chip technology for drug discovery, creation of highly biomimetic disease state models, and emphasize interventional radiology (IR) applications.
Materials & Methods
Advances in the field now allow for three-dimensional (3D) bioprinted models within a microdevice, creating a biomimetic system using human cells and blood components. Of particular note to IR, tissue obtained by biopsy can be loaded onto a chip & subjected to drugs to understand susceptibility, toxicity, and metabolism. In oncology, it can be utilized to learn the effects of radiosensitizers prior to application of therapeutic radioactive material. Probes in microfluidic channels can study irreversible electroporation, microwave, cryo- and radio frequency ablation on tumor tissue. Microfluidics can underpin the personalization in management of disease.
Results
A microfluidic chip is a set of micro-channels in glass, silicone, or a polymer, such as polydimethylsiloxane. The micro-channels are interconnected creating a network amenable to external manipulation by various liquids and gases. An organ-on-a-chip is a microfluidic cell culture device containing living cells. This arrangement is utilized to simulate tissue and organ physiology to a degree impossible with 2D or static 3D cultures. Furthermore, they are capable of integrating multiple laboratory functions into one cohesive unit. They are amenable to high-resolution, real-time imaging, genetic and biochemical analysis. Organs-on-chips are in development allowing advanced investigation of drug interactions and discovery.
Conclusions
Microfluidic bioreactors in medicine and IR can enhance understanding of disease thereby changing directions for research ultimately shifting clinical practice to treat patients in a customized approach.
Final ID
598
Type
Educational Exhibit-Poster Only
Authors
S Behravesh1, Y Zhang2, P Hoang3, S Naidu1, E Huettl3, M Knuttinen1, A Deipolyi4, R Oklu3
Institutions
1Mayo Clinic Arizona, Scottsdale, AZ, 2Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 3Mayo Clinic Arizona, Phoenix, AZ, 4Memorial-Sloan Kettering Cancer Center, New York, NY
Purpose
To review current and future applications of microfluidic bioreactors. To highlight the potential of lab-on-a-chip technology for drug discovery, creation of highly biomimetic disease state models, and emphasize interventional radiology (IR) applications.
Materials & Methods
Advances in the field now allow for three-dimensional (3D) bioprinted models within a microdevice, creating a biomimetic system using human cells and blood components. Of particular note to IR, tissue obtained by biopsy can be loaded onto a chip & subjected to drugs to understand susceptibility, toxicity, and metabolism. In oncology, it can be utilized to learn the effects of radiosensitizers prior to application of therapeutic radioactive material. Probes in microfluidic channels can study irreversible electroporation, microwave, cryo- and radio frequency ablation on tumor tissue. Microfluidics can underpin the personalization in management of disease.
Results
A microfluidic chip is a set of micro-channels in glass, silicone, or a polymer, such as polydimethylsiloxane. The micro-channels are interconnected creating a network amenable to external manipulation by various liquids and gases. An organ-on-a-chip is a microfluidic cell culture device containing living cells. This arrangement is utilized to simulate tissue and organ physiology to a degree impossible with 2D or static 3D cultures. Furthermore, they are capable of integrating multiple laboratory functions into one cohesive unit. They are amenable to high-resolution, real-time imaging, genetic and biochemical analysis. Organs-on-chips are in development allowing advanced investigation of drug interactions and discovery.
Conclusions
Microfluidic bioreactors in medicine and IR can enhance understanding of disease thereby changing directions for research ultimately shifting clinical practice to treat patients in a customized approach.